We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Hospitalized patients who require strict ...

Marks approval of first concentrated mealtime insulin analog in the U.S. and expands Lilly's portfolio of medicines for people with type 1 and type 2 diabetes INDIANAPOLIS, May 27, 2015 /PRNewswire/ - ...

INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Humalog ® 200 units/mL KwikPen ® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a ...

ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...

Type 2 diabetes is a chronic metabolic condition characterised by insulin resistance and insufficient pancreatic insulin production, resulting in high blood glucose levels. Type 2 diabetes is commonly ...

In this period he received almost 3000 gm. of carbohydrate (1425 gm. by vein and about 1400 gm. by mouth), but the urine remained sugar free most of the time and the blood sugar never exceeded 54 mg.

High-strength insulin products such as insulin glargine 300 units/ml (Toujeo) have been developed for people with type 1 or type 2 diabetes who have large daily insulin requirements to reduce the ...

(MENAFN- PR Newswire) INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly and Company's (NYSE: LLY ) rapid-acting ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...